La NMPA de China otorga la aprobación condicional para la inyección de remestemcel-L-rknd

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Ryoncil #remestemcelLrknd #aGVHD #GraftVersusHostDisease #StemCellTherapy #NMPA #DrugApproval #CellTherapy #Biotech #Hematology

Mesoblast stock soars after reporting first Ryoncil sales Investing.com -- Mesoblast Ltd (NASDAQ:MESO) stock surged 25% after the company reported its first quarter of sales for its newly approved drug Ryoncil, which generated $13.2 million in gross revenue. The cellular medicines company launched Ryoncil on March 28, 2025, following FDA approval for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children. Ryoncil is the first and only FDA-approved mesenchymal stromal cell product in the United States. In addition to product sales, Mesoblast reported $1.6 million in royalty revenue from its Japanese licensee for TEMCELL HS Inj. The company ended the quarter with a strong cash position of $162 million as of June 30. The commercial rollout is progressing steadily, with more than 25 transplant centers onboarded since launch. Mesoblast expects to complete onboarding across all 45 priority transplant centers this quarter, which account for approximately 80% of U.S. pediatric transplants. Insurance coverage for Ryoncil continues to expand, now covering over 250 million U.S. lives through commercial and government payers. Notably, mandatory fee-for-service Medicaid coverage became effective July 1 in all U.S. states. The company has established patient access programs through its MyMesoblast hub to ensure treatment accessibility. Ryoncil also received seven years of orphan-drug exclusivity from the FDA, providing market protection through 2032, in addition to biologic exclusivity preventing biosimilar entry until December 2036. Mesoblast is working to expand Ryoncil’s label to include adults with SR-aGvHD and continues development of its other pipeline products for chronic inflammatory heart failure and low back pain. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if MESO is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Mesoblast #Ryoncil #Investing #StockMarket #Pharmaceuticals

The Rollercoaster Journey of Mesenchymal Stromal Cells and Their Impact on Medicine Explore the remarkable journey of mesenchymal stromal cells (MSCs) from confusion to clinical breakthroughs, shaping future medical therapies.

The Rollercoaster Journey of Mesenchymal Stromal Cells and Their Impact on Medicine #Ryoncil #Mesenchymal_Stromal_Cells #Tasly

First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine The FDA has granted approval for RYONCIL®, the first therapy using mesenchymal stromal cells (MSCs) to treat children with a rare condition, marking a significant milestone for regenerative medicine.

First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine #United_States #New_York #Ryoncil #MSC #Osiris_Therapeutics

ISCT Celebrates Historic FDA Approval of RYONCIL for Pediatric GvHD Treatment in the U.S. The landmark FDA approval of RYONCIL for treating steroid-refractory acute GvHD in children marks a significant advance in MSC therapies, according to ISCT.

ISCT Celebrates Historic FDA Approval of RYONCIL for Pediatric GvHD Treatment in the U.S. #United_States #Vancouver #FDA #Ryoncil #Mesoblast

FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol

Yesterday, #Ryoncil became the first FDA-approved mesenchymal stromal #celltherapy indicated to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients who are two months and older. #stemcells www.fda.gov/news-events/...

FDA Makes History by Approving Ryoncil as First MSC Therapy for Pediatric Patients The FDA has approved Ryoncil, the first-ever mesenchymal stromal cell therapy, designed specifically for children suffering from steroid-refractory acute graft-versus-host disease.

FDA Makes History by Approving Ryoncil as First MSC Therapy for Pediatric Patients #United_States #FDA_Approval #Silver_Spring #Ryoncil #MSC_Therapy